Payment overview · 2025
General Payments
$419.23
23 reported records · 15 companies
Healthcare provider profile · identity verified
Casey Joseph Henich, MD
Allopathic & Osteopathic Physicians|Family Medicine · WEST VALLEY CITY, UT · NPI 1003041740
Verified facts
What the public records show
CMS Open Payments records show Casey Joseph Henich, MD received $419.23 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $80.58 | 19.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.21 | 11.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.71 | 9.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.29 | 7.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.57 | 6.8% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $26.15 | 6.2% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $24.72 | 5.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.37 | 5.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.84 | 5.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.75 | 5.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.07 | 5.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.46 | 3.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.46 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.17 | 3.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.88 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $419.23 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $80.58 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $48.21 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $48.21 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.71 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 280 | 78 |
| Lisinopril | Lisinopril | 210 | 58 |
| Metformin Hcl | Metformin Hcl | 203 | 55 |
| Omeprazole | Omeprazole | 186 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 167 | 44 |
| Gabapentin | Gabapentin | 165 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 35 |
| Trazodone Hcl | Trazodone Hcl | 126 | 27 |
| Simvastatin | Simvastatin | 117 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 104 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 81 | 17 |
| Sertraline Hcl | Sertraline Hcl | 78 | 19 |
| Ibuprofen | Ibuprofen | 75 | 21 |
| Furosemide | Furosemide | 65 | 19 |
| Losartan Potassium | Losartan Potassium | 65 | 20 |
| Carvedilol | Carvedilol | 63 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 16 |
| Alendronate Sodium | Alendronate Sodium | 59 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 16 |
| Metformin Hcl Er | Metformin Hcl | 49 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Allopurinol | Allopurinol | 44 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Prednisone | Prednisone | 37 | 26 |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Finasteride | Finasteride | 36 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Lamotrigine Er | Lamotrigine | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $419.23 · 23 records | ABBVIE INC. | AREXVY, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, GARDASIL 9, GVOKE HYPOPEN, M-M-R II, MOUNJARO, NURTEC ODT, OTEZLA, PROQUAD, REPATHA, SAPIEN 3 Ultra RESILIA, SHINGRIX, SPINRAZA, TZIELD, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error